Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 8, 2008 - Issue 12
Submit an article Journal homepage
221
Views
13
CrossRef citations to date
0
Altmetric
Drug Evaluations

Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sézary syndrome

Dominik Sebastian Mestel Charité Universitaetsmedizin Berlin, Skin Cancer Center Charite, Department of Dermatology and Allergy, Charitéplatz 1, DE-10117, Berlin, Germany +49 30 450 518 213; +49 30 450 518 509; [email protected]
, MD,
Marc Beyer Charité Universitaetsmedizin Berlin, Skin Cancer Center Charite, Department of Dermatology and Allergy, Charitéplatz 1, DE-10117, Berlin, Germany +49 30 450 518 213; +49 30 450 518 509; [email protected]
, MD,
Markus Möbs Charité Universitaetsmedizin Berlin, Skin Cancer Center Charite, Department of Dermatology and Allergy, Charitéplatz 1, DE-10117, Berlin, Germany +49 30 450 518 213; +49 30 450 518 509; [email protected]
, PhD,
Matthias Steinhoff Charité Universitaetsmedizin Berlin, Skin Cancer Center Charite, Department of Dermatology and Allergy, Charitéplatz 1, DE-10117, Berlin, Germany +49 30 450 518 213; +49 30 450 518 509; [email protected]
, MD,
Wolfram Sterry Charité Universitaetsmedizin Berlin, Skin Cancer Center Charite, Department of Dermatology and Allergy, Charitéplatz 1, DE-10117, Berlin, Germany +49 30 450 518 213; +49 30 450 518 509; [email protected]
, MD &
Chalid Assaf Charité Universitaetsmedizin Berlin, Skin Cancer Center Charite, Department of Dermatology and Allergy, Charitéplatz 1, DE-10117, Berlin, Germany +49 30 450 518 213; +49 30 450 518 509; [email protected]
, MD
Pages 1929-1939 | Published online: 06 Nov 2008

Bibliography

  • Diamandidou E, Colome-Grimmer M, Fayad L, et al. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. Blood 1998;92:1150-9
  • Siegel RS, Pandolfino T, Guitart J, et al. Primary cutaneous T-cell lymphoma: review and current concepts. J Clin Oncol 2000;18:2908-25
  • Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. N Engl J Med 2004;350:1978-88
  • Paulli M, Berti E. Cutaneous T-cell lymphomas (including rare subtypes). Current concepts. II. Haematologica 2004;89:1372-88
  • Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol 2007;143:854-95
  • Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007;110:1713-22
  • Kim YH, Jensen RA, Watanabe GL, et al. Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. Arch Dermatol 1996;132:1309-13
  • Whittaker SJ, Foss FM. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma. Cancer Treat Rev 2007;33:146-60
  • Zackheim HS, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides. Experience in 79 patients. Arch Dermatol 1998;134:949-54
  • Zackheim HS. Topical carmustine (BCNU) in the treatment of mycosis fungoides. Dermatol Ther 2003;16:299-302
  • Ramsay DL, Halperin PS, Zeleniuch-Jacquotte A. Topical mechlorethamine therapy for early stage mycosis fungoides. J Am Acad Dermatol 1988;19:684-91
  • Breneman D, Duvic M, Kuzel T, et al. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol 2002;138:325-32
  • Ramsay DL, Lish KM, Yalowitz CB, et al. Ultraviolet-B phototherapy for early-stage cutaneous T-cell lymphoma. Arch Dermatol 1992;128:931-3
  • Querfeld C, Rosen ST, Kuzel TM, et al. Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch Dermatol 2005;141:305-11
  • Olsen EA. Interferon in the treatment of cutaneous T-cell lymphoma. Dermatol Ther 2003;16:311-21
  • Wollina U, Dummer R, Brockmeyer NH, et al. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 2003;98:993-1001
  • Greiner D, Olsen EA, Petroni G. Pentostatin (2′-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 1997;36:950-5
  • Marchi E, Alinari L, Tani M, et al. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: Phase II study of 32 patients. Cancer 2005;104:2437-41
  • Coors EA, Von Den Driesch P. Treatment of erythrodermic cutaneous T-cell lymphoma with intermittent chlorambucil and fluocortolone therapy. Br J Dermatol 2000;143:127-31
  • Akpek G, Koh HK, Bogen S, et al. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Cancer 1999;86:1368-76
  • Kaye FJ, Bunn PA, Jr, Steinberg SM, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1998;321:1784-90
  • Bachelez H, Bagot M, Beylot-Barry M, et al. Therapy algorithm for cutaneous T-cell lymphomas. Ann Dermatol Venereol 2005;132:43-4
  • Demierre MF, Foss FM, Koh HK. Proceedings of the International Consensus Conference on Cutaneous T-cell Lymphoma (CTCL) Treatment Recommendations. Boston, Massachusetts, Oct.1 and 2, 1994. J Am Acad Dermatol 1997;36:460-6
  • Trautinger F, Knobler R, Willemze R, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 2006;42:1014-30
  • Demierre MF, Gan S, Jones J, et al. Significant impact of cutaneous T-cell lymphoma on patients´ quality of life. Cancer 2006;109:1799-803
  • Negro-Vilar A, Dziewanowska Z, Groves ES, et al. Efficacy and safety of denileukin diftitox (Dd) in a Phase III, double-blind, placebo-controlled study of CD25+ patients with cutaneous T-cell lymphoma (CTCL). J Clin Oncol (ASCO Meeting Abstracts) 2007;25:8026
  • Foss F, Demierre MF, DiVenuti G. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 2005;106(2):454-7
  • Piekarz R, Frye R, Wright J, et al. Update of the NCI multiinstitutional Phase II trial of romidepsin, FK228, for patients with cutaneous or peripheral T-cell lymphoma. J Clin Oncol (ASCO Meeting Abstracts) 2007;25:8027
  • Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007;109:31-9
  • Advani R, Hymes K, Pohlman B, et al. Belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma: results of a Phase II study. Blood (ASH Annual Meeting Abstracts) 2007;110:3453
  • Prince M, George D, Johnstone R, et al. LBH589, a novel deacetylase inhibitor (DACi), treatment of patients with cutaneous T-cell lymphoma (CTCL). Skin expression profiles in the first 24 h related to clinical response following therapy. Blood 2006;108:2715
  • Timmermann S, Lehrmann H, Polesskaya A, et al. Histone acetylation and disease. Cell Mol Life Sci 2001;58:728-36
  • Rasheed WK, Johnstone RW, Prince HM. Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs 2007;16:659-78
  • Marchion D, Münster P. Development of histone deacetylase inhibitors for cancer treatment. Expert Rev Anticancer Ther 2007;7:583-98
  • Chauhan D, Hideshima T, Mitsiades C, et al. Proteasome inhibitor therapy in multiple myeloma. Mol Cancer Ther 2005;4(4):686-92
  • Sors A, Jean-Louis F, Bégué E, et al. Inhibition of IκB Kinase subunit 2 in cutaneous T-cell lymphoma down-regulates nuclear factor-κB constitutive activation, induces cell death, and potentiates the apoptotic response to antineoplastic chemotherapeutic agents. Clin Cancer Res 2008;14:901-11
  • Zinzani PL, Musuraca G, Tani M, et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25:4293-7
  • Duvic M, Forero-Torres A, Foss F, et al. Response to oral forodesine in refractory cutaneous T-cell lymphoma: interim results of a Phase I/II study. ASH Annual Meeting Abstracts. Blood 2007;110:122
  • Dearden CE, Matutes E, Catovsky D. Alemtuzumab in T-cell malignancies. Med Oncol 2002;19:27-32
  • Kennedy GA, Seymour JF, Wolf M, et al. Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab. Eur J Haematol 2003;71:250-6
  • Villadsen LS, Skov L, Dam TN, et al. In situ depletion of CD4+ T cells in human skin by Zanolimumab. Arch Dermatol Res 2007;298:449-55
  • Villadsen LS, Havenith CEG, Skov L, et al. Depletion of human CD4+ T cells in peripheral blood and skin by HuMax-CD4. J Invest Dermatol 2004;123:2-156
  • Marschner S, Hunig T, Cambier JC, et al. Ligation of human CD4 interferes with antigen-induced activation of primary T-cells. Immunol Lett 2002;82:131-9
  • Genmab drops HuMax-CD4 for psoriasis. Genmab A/S PRESS Release; 15 December 2003
  • Genmab halts HuMax-CD4 RA trials. Genmab A/S PRESS Release; 25 September 2002
  • Duvic M, Kim Y, Korman NJ, et al. Zanolimumab, a fully human monoclonal antibody: Early results of an ongoing clinical trial in patients with CD4+ mycosis fungoides (MF) type CTCL (stage IB-IVB) who are refractory or intolerant to targretin and one other standard therapy. Blood (ASH Annual Meeting Abstracts) 2006;108:2731
  • Genmab anounces early results of ongoing HuMax-CD4 trials. Genamab A/S Press Release 10 December 2006. Available from: http://www.genmab.com/PressCentre/ArchivedNewsReleases/2006/55GenmabAnnouncesEarlyResultsofOngoingHuMax-CD4Trials/Language/English.aspx [last accessed 10 October 2008]
  • Fishwild DM, O´Donnell SL, Bengoechea T, et al. High-avidity human IgGk monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat Biotechnol 1996;14:845-51
  • Rider DA, Havenith CE, De Ridder R, et al. A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity. Cancer Res 2007;67:9945-53
  • Veillette A, Bookman MA, Horak EM, et al. Signal transduction through the CD4 receptor involves the activation of the internal membrane tyrosine- protein kinase p56Ick. Nature 1989;338:257-9
  • Janssen E, Zhang W. Adapter proteins in lymphocyte activation. Curr Opin Immunol 2003;15:269-76
  • Damen JE, Liu L, Rosten P, et al. The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-triphosphate 5-phosphatase. Proc Natl Acad Sci USA 1996;93:1689-93
  • Toker A, Cantley LC. Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature 1997;387:673-6
  • Cantrell D. Protein kinase B (Akt) regulation and function in T lymphocytes. Semin Immunol 2002;14:19-26
  • Kane LP, Mollenauer MN, Xu Z, et al. Akt-dependent phosphorylation specifically regulates Cot induction of NF-ĸB-dependent transcription. Mol Cell Biol 2002;22:5962-74
  • Skov L, Kragballe K, Zachariae C, et al. HuMax-CD-4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris. Arch Dermatol 2003;139:1433-9
  • Fishwild DM, Hudson DV, Deshpande U, et al. Differential effects of administration of a human anti-CD4 monoclonal antibody, HM6G, in nonhuman primates. Clin Immunol 1992;92:138-52
  • Kim YH, Duvic M, Obitz E, et al. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 2007;109:4655-62
  • Rowan W, Tite J, Topley P, et al. Cross-linking of the CAMPATH-1 antigen (CD-52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology 1998;95:427-36
  • Lundin J, Hagberg H, Repp JR, et al. Phase II Study of Alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndrome. Blood 2003;101:4267-72
  • Lenihan DJ, Alencar AJ, Yang D, et al. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome. Blood 2004;104:655-8
  • Thursky KA, Worth LJ, Seymour JF, et al. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br J Haematol 2006;132:3-12
  • Lundin J, Kennedy B, Dearden C, et al. No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sézary syndrome. Blood 2005;105:4148-9
  • Lenihan DJ, Alencar AJ, Yang D, et al. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome. Blood 2004;104:655-8
  • Olsen E, Duvic M, Frankel A, et al. Pivotal Phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001;19:376-88
  • Duvic M, Hymes K, Heald P, et al. Bexarotene Worldwide Study Group. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational Phase II-III trial results. J Clin Oncol 2001;19:2456-71
  • Stadler R, Assaf C, Klemke CD, et al. Short German guidelines: cutaneous lymphomas. J Dtsch Dermatol Ges 2008;6: S25-31

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.